Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 3/20 | 0.83 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.83 |
| ▸ | DRD2 | P14416 | 2/20 | 0.83 |
| ▸ | DRD3 | P35462 | 2/20 | 0.83 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.77 |
| ▸ | POLB | P06746 | 1/20 | 0.77 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.73 |
| ▸ | SLC6A12 | P48065 | 1/20 | 0.70 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.70 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.70 |
| ▸ | RECQL | P46063 | 1/20 | 0.70 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.69 |
| ▸ | DCUN1D1 | Q96GG9 | 4/20 | 0.67 |
| ▸ | UBE2M | P61081 | 2/20 | 0.67 |
| ▸ | HTT | P42858 | 1/20 | 0.66 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.66 |
| ▸ | CCR3 | P51677 | 2/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31616382 | 0.93 | CCR3 (0.74) | DRD4KMT2ADRD2DRD3ALDH1A1 | |
| SCHEMBL31616363 | 0.93 | CCR3 (0.74) | DRD4KMT2ADRD2DRD3ALDH1A1 | |
| SCHEMBL9078087 | 0.91 | DRD4 (1.00) | DRD4KMT2ADRD2DRD3ALDH1A1 | |
| SCHEMBL18657866 | 0.89 | DRD4 (0.85) | DRD4KMT2ADRD2DRD3ALDH1A1 | |
| SCHEMBL12677059 | 0.89 | DRD4 (0.85) | DRD4KMT2ADRD2DRD3ALDH1A1 | |
| SCHEMBL12677054 | 0.87 | KMT2A (1.00) | DRD4KMT2ADRD2DRD3ALDH1A1 | |
| SCHEMBL18657999 | 0.87 | DRD4 (0.81) | DRD4KMT2ADRD2DRD3ALDH1A1 | |
| SCHEMBL22820100 | 0.83 | SIGMAR1 (0.67) | DRD4KMT2ADRD2DRD3ALDH1A1 | |
| SCHEMBL14433853 | 0.83 | KMT2A (0.79) | DRD4KMT2ADRD2DRD3ALDH1A1 | |
| SCHEMBL5862050 | 0.82 | SIGMAR1 (1.00) | SIGMAR1CCR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2023-01-19 | — | — | US | disclosed |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-09-14 | — | — | US | disclosed |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | MEMORIAL SLOAN KETTERING CANCER CENTER (US) | 2021-03-11 | — | — | US | disclosed |
| WO-2017049295-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | ST. JUDE CHILDREN'S RESEARCH HOSPITAL (US) | 2017-03-23 | — | — | WO | disclosed |
| EP-1140836-B1 | AMIDE COMPOUNDS | ASTELLAS PHARMA INC (JP) | 2011-03-23 | — | — | EP | disclosed |
| US-6710043-B1 | POSSESS THE POTENTIATION OF THE CHOLINERGIC ACTIVITY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2004-03-23 | — | — | US | disclosed |
| US-20040014745-A1 | Amide compounds | FUJISAWA PHARMACEUTICAL CO. LTD. (JP) | 2004-01-22 | — | — | US | disclosed |
| EP-1235575-A2 | AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2002-09-04 | — | — | EP | disclosed |
| WO-2000072834-A9 | AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO (JP) | 2001-12-20 | — | — | WO | disclosed |
| WO-2000072834-A2 | AGENT FOR EXPRESSION OF LONG-TERM POTENTIATION OF SYNAPTIC TRANSMISSION COMPRISING COMPOUND HAVING BRAIN SOMATOSTATIN ACTIVATION PROPERTY | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 2000-12-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230021224-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | DRD4 2929/4885KMT2A 2316/4885DRD2 4060/4885 |
| US-11116757-B2 | Methods and compositions of inhibiting DCN1-UBC12 interaction | UBQLN1, CUL1, DCUN1D1 | DRD4 2929/4885KMT2A 2316/4885DRD2 4060/4885 |
| US-20040014745-A1 | Amide compounds | CHRM1, CHRM2, CHRNE | DRD4 323/4885KMT2A 1224/4885DRD2 177/4885 |
| US-20210069172-A1 | METHODS AND COMPOSITIONS OF INHIBITING DCN1-UBC12 INTERACTION | UBQLN1, CUL1, DCUN1D1 | DRD4 2929/4885KMT2A 2316/4885DRD2 4060/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.